67765-42-8

Usage

Uses

Used in Pharmaceutical Research:
5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione is used as a building block in pharmaceutical research for its potential to contribute to the development of new drugs. Its unique chemical structure allows it to be a versatile component in the synthesis of various medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione is employed as a key intermediate. Its reactivity and structural features make it suitable for the creation of a wide range of organic compounds, facilitating advancements in chemical research and development.
Used in Antithrombotic Applications:
5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione is studied for its potential as an anticoagulant, which could be utilized in the prevention and treatment of blood clot-related conditions. Its ability to modulate coagulation pathways makes it a promising candidate for further research and development in this therapeutic area.
Used as a Biological Receptor Ligand:
5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione is also recognized for its capacity to act as a ligand for various biological receptors. Its interaction with these receptors could have implications in the modulation of biological processes, making it a candidate for the development of drugs targeting specific receptor-mediated pathways.

Upstream product

• 14963-96-3 3-methoxyphthalic anhydride 
• 60144-52-7 tert-butyl 3-methoxyphenylcarbamate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 53600-33-2 6-methoxyanthranilic acid 
• 76-02-8 trifluoroacetyl chloride 
• 136247-94-4 N-(tert-butoxycarbonyl)-6-methoxyanthranilic acid 
• 75-44-5 phosgene 
• 536-90-3 m-Anisidine 

Downstream Products

• 681247-48-3 methyl 6-amino-3-bromo-2-methoxybenzoate 
• 681247-97-2 methyl 6-amino-2-methoxy-3-vinylbenzoate 
• 681247-98-3 methyl 6-amino-3-ethyl-2-methoxybenzoate 
• 943138-68-9 C₁₃H₁₃NO₄ 
• 943139-02-4 C₁₉H₁₅BrFNO₆S 
• 943138-70-3 C₁₃H₁₃NO₄ 
• 943138-72-5 C₁₂H₁₃N₃O₃ 
• 943138-74-7 C₁₂H₁₃N₃O₃ 
• 681247-11-0 methyl 6-amino-3-bromo-2-hydroxybenzoate 
• 681247-12-1 methyl 6-amino-3-bromo-2-ethoxybenzoate 
• 681247-19-8 methyl 3-bromo-2-ethoxy-6-{[(4-fluorophenyl)sulfonyl]amino}benzoate 

Relevant academic research and scientific papers

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Synthesis and nematicidal activities of 1,2,3-benzotriazin-4-one containing 4,5-dihydrothiazole-2-thiol derivatives against Meloidogyne incognita

A series of novel 1,2,3-benzotriazin-4-one derivatives containing 4,5-dihydrothiazole-2-thiol were synthesized and characterized by 1H NMR, 13C NMR, 19F NMR and HRMS. The bioassay results showed that compounds 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-7-methoxybenzo[d][1–3]triazin-4(3H)-one, 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-6-nitrobenzo[d][1–3]triazin-4(3H)-one, 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one exhibited good control efficacy against the cucumber root-knot nematode disease caused by Meloidogyne incognita at the concentration of 10.0 mg L?1 in vivo. Compound 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one showed excellent nematicidal activity with inhibition 68.3% at a concentration of 1.0 mg L?1. It suggested that the structure of 1,2,3-benzotriazin-4-one containing 4,5-dihydro-thiazole-2-thiol could be optimized further.

Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket

Clinical use of phosphodiesterase-5 (PDE5) inhibitors is limited by several side effects due to weak isoform selectivity. Herein, a unique allosteric pocket of PDE5 is identified by molecular modeling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO). The crystal structure of PDE5 with bound EVO derivative (S)-7e revealed that binding of (S)-7e to the novel allosteric pocket induced dramatic conformation changes in the H-loop with a maximum 24 ? movement of their Cα atoms. This movement directly blocks the binding of substrate/inhibitors to the PDE5 active site, which is different from all traditional PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil. These derivatives showed >570-fold selectivity over PDE6C and PDE11A and achieved potent efficacy for the effective treatment of pulmonary hypertension in vivo.

Synthesis and nematicidal evaluation of 1,2,3-benzotriazin-4-one derivatives containing piperazine as linker against Meloidogyne incognita

To explore new skeleton with nematicidal activity, a series of novel 1,2,3-benzotriazin-4-one derivatives containing piperazine as linker were synthesized and varied fragments were also introduced to increase structure diversity of the new skeleton. Their inhibitory activities in vivo were evaluated against Meloidogyne incognita. The newly prepared compounds A6, A8, A21, A28 and A38 exhibited more than 50% inhibition at the concentration of 20 mg/L. Especially compound A6 displayed 71.4% inhibition against Meloidogyne incognita at the concentration of 20 mg/L. The nematicidal activities varied significantly depending on the types and positions of the substituents, which provided guidance for further structure modification.

Evodiamine compounds and preparation method and application thereof

The invention discloses evodiamine compounds and a preparation method and application thereof. The evodiamine compounds adopt structures shown as a general formula (I), and comprise racemates, d-type or l-type isomers and pharmaceutically acceptable salts thereof. Pharmacological tests prove that the evodiamine compounds have obvious phosphodiesterase PDE5 inhibiting activity, some of the evodiamine compounds have equivalent PDE5 inhibiting activity to sildenafil, and the evodiamine compounds have stronger phosphodiesterase PDE6 selectivity. The evodiamine compounds can be clinically used for improving or treating symptoms or diseases in a cardiovascular system, a cerebrovascular system and a urinary system, especially improving or treating symptoms or diseases including erectile dysfunction and pulmonary hypertension.

Derivative of azaphenalene-3-ketone and preparation method and application thereof

The invention relates to a derivative of azaphenalene-3-ketone and a preparation method and an application thereof and belongs to the technical field of medicine synthesis. The structure of the derivative is as follows: a formula as shown in the descripti

Quinazoline dione derivatives and preparation method and application thereof

The invention provides novel quinazoline dione derivatives and a preparation method and application thereof. The compounds include compounds with the structure shown in the general formula V in the description and pharmaceutically acceptable salts or hydrates thereof. The compounds are active ligands of novel cannabinoid II receptors (CB2) and can be used for preparing medicine for treating, preventing and relieving CB2 receptor-mediated diseases, wherein the medicine is an agonist or partial agonist or inverse agonist or antagonist of CB2 receptors.

2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties

A series of 2-pyridylquinolones has been prepared in 5-7 steps and through lead optimisation, antimalarial activity as low as 12 nM against Plasmodium falciparum (Pf) has been achieved. Compared with previous analogues in this series, selected molecules h

Structure-activity relationship and properties optimization of a series of Quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway

Wnt signaling pathway plays a critical role in numerous cellular processes, including tumor initiation, proliferation, invasion/infiltration, metastasis formation and resistance to chemotherapy. In a drug discovery project aimed at the identification of inhibitors of the canonical Wnt pathway, we selected a series of quinazoline 2,4-diones as starting point for the therapeutic treatment of glioblastoma multiforme. Despite of poor physico-chemical properties of hit compound 1, our medicinal chemistry effort allowed the discovery and characterization of lead compound 33 (SEN461), with improved ADME profile, good bioavailability and active in vitro and in vivo in glioblastoma, gastric and sarcoma tumors.

Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer

Ingenol 3-benzoates were investigated with respect to chemical stability, pro-inflammatory effects, cell death induction and PKCδ activation. A correlation between structure, chemical stability and biological activity was found and compared to ingenol mebutate (ingenol 3-angelate) used for field treatment of actinic keratosis. We also provided further support for involvement of PKCδ for induction of oxidative burst and cytokine release. Molecular modeling and dynamics calculations corroborated the essential interactions between key compounds and C1 domain of PKCδ.